Results 291 to 300 of about 68,775 (341)

In silico analysis of pressure distribution and flow profiles across an experimental left ventricular assist device accessory. [PDF]

Interdiscip Cardiovasc Thorac Surg
Osypka A, Meissner F, Ozturk D, Windisch R, Vestner H, Costa Galbas M, Czerny M, Bothe W.   +7 more
europepmc   +1 more source

Rationale and design of the randomized ‘early ventricular assist device’—Trial (VAD‐DZHK3)

ESC Heart Failure, EarlyView.
The VAD‐DZHK3 trial is a randomised controlled study evaluating whether elective LVAD implantation improves outcomes in end‐stage heart failure (HF) patients listed for heart transplantation compared with delayed implantation after clinical deterioration.
Christoph Knosalla, Gloria Färber, Andreas J. Rieth, Rolf Wachter, Marius Placzek, Wolfgang Albert, Gerd Hasenfuß, Volkmar Falk, Tim Friede, for the VAD‐DZHK3 Investigators   +9 more
wiley   +1 more source

Antiarrhythmics and double-sequential external defibrillation for management of incessant ventricular fibrillation in a left ventricular assist device. [PDF]

HeartRhythm Case Rep
Becerra AF, Parker AM, Al-Ani MA, Vilaro JR, Aranda JM, Ahmed MM.   +5 more
europepmc   +1 more source

The pulmonary artery pulsatility index in patients with severe aortic stenosis undergoing valve replacement

ESC Heart Failure, EarlyView.
Abstract Background and aims The pulmonary artery pulsatility index (PAPi), that is, the pulmonary artery pulse pressure (PAPP) divided by the mean right atrial pressure (mRAP), is an increasingly used invasive index of right ventricular function. We sought to assess the prognostic impact of the PAPi in unselected patients with aortic stenosis (AS ...
Laura A. Rechsteiner, Lukas Weber, Philipp K. Haager, Johannes Rigger, Joannis Chronis, Peter Ammann, Roman Brenner, Martin O. Schmiady, Hans Rickli, Micha T. Maeder   +9 more
wiley   +1 more source

The role of intra‐abdominal pressure and point of care ultrasound to guide decongestive therapies in acute heart failure

ESC Heart Failure, EarlyView.
The ABDOPOCUS‐HF trial is a randomized, single‐blind, low‐intervention clinical trial (n = 168) investigating the utility of intra‐abdominal pressure (IAP) and point of care ultrasound to guide decongestive therapies during the first 72 hours after admission for acute heart failure.
C. Josa‐Laorden, A. Campos‐Saenz de Santamaría, S. Crespo‐Aznarez, J. Pérez‐Silvestre, E. Montero‐Hernandez, P. Llacer‐Iborra, J. Torres‐Macho, M. Méndez‐Bailon, J.L. Morales‐Rull, P. Salamanca‐Bautista, N. Fernández‐Villa, I. Torres‐Courchoud, M.A. Vázquez‐Ronda, R. Martínez‐Gutiérrez, P. Serrano‐Irigoyen, N. García‐Lorente, J.C. Trullas, M. Cobo‐Marcos, M.J. Pinilla, M. Sánchez‐Marteles, J. Rubio‐Gracia   +20 more
wiley   +1 more source

2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias [PDF]

, 2019
Cuculich, Phillip, et al,
core   +1 more source

Understanding embolus transport and source to destination mapping of thromboemboli in hemodynamics driven by left ventricular assist device. [PDF]

Sci Rep
Majee S, Sahni A, Pal JD, McIntyre EE, Mukherjee D.   +4 more
europepmc   +1 more source

Initial clinical experience with dapagliflozin in addition to optimized medical therapy in paediatric heart failure patients

ESC Heart Failure, EarlyView.
Abstract Aims Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT2) inhibitor, has shown clinical benefits in adults with heart failure (HF), improving cardiac function, reducing HF‐related hospitalizations and enhancing survival rates. While extensively studied in adult HF, data on its efficacy and safety in paediatric HF patients remain limited. We
Lisa‐Maria Rosenthal, Oliver Miera, Annemarie Krauss, Friederike Danne, Felix Berger, Peter Kramer   +5 more
wiley   +1 more source

Left Ventricular Assist Device Implantation Under Argatroban Anticoagulation in Heparin-Induced Thrombocytopenia: A Literature Review and Clinical Case Presentation. [PDF]

J Clin Med
Kšela J, Kafol J, Kerin M, Pirc D, Novak R, Goslar T.   +5 more
europepmc   +1 more source

Prognostic impact of peak oxygen consumption in heart failure: A systematic review and meta‐analysis

ESC Heart Failure, EarlyView.
Based on 64 studies, each 1 mL/kg/min increase in VO2peak significantly reduced all‐cause mortality (HR: 0.86, 95% CI 0.82–0.90) and combined outcomes of ventricular assist device, transplant and all‐cause mortality (HR: 0.84, 95% CI 0.79–0.89) in patients with heart failure, though no significant association was observed with cardiovascular mortality (
Konstantinos Prokopidis, Krzysztof Irlik, Julia Piaśnik, Zuzanna Michalska, Mirela Hendel, Katarzyna Nabrdalik, Gregory Y.H. Lip   +6 more
wiley   +1 more source